Compare MasTec Inc (MTZ) vs Pfizer Inc (PFE) Price & Performance

MasTec (MTZ) trades at $272.46, up 5.35% with strong YTD performance of 25.9%, outperforming the S&P 500. The stock shows bearish technical signals but maintains robust fundamentals with record Q2 2026 revenue of $4.37B and 40% EBITDA growth. Recent acquisition of The Superior Group for $1.65B expands critical infrastructure capabilities. The company raised 2026 guidance citing strong infrastructure demand and a record $21.4B backlog.

Despite technical weakness, MasTec's strong earnings momentum and 88.9% analyst buy rating with $447.91 price target suggest significant upside. Key risks include execution of large acquisitions and communications segment delays. The stock offers exposure to infrastructure growth trends but faces near-term technical headwinds.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.